
Teladoc Health Faces Investor Probe Following Revenue Guidance Cut
A 30% collapse in Teladoc Health share value has triggered a formal securities investigation into the company’s financial disclosures. The probe focuses on whether leadership provided misleading revenue projections after the firm slashed its full-year 2026 outlook by more than $100 million just months after initial guidance.


























